Pharmacokinetic considerations in treating invasive pediatric fungal infections

References

• Castagnola E, Cesaro S, Giacchino M, et al. Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr Infect Dis J. 2006;25:634–639.
   PubMed Web of Science ®Google Scholar
• Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990;12(Suppl 3):S318–S326.
   PubMedGoogle Scholar
• Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009;68:906–915.
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Roos B, Heep M, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50:279–285.
   PubMed Web of Science ®Google Scholar
• Lim SG, Sawyerr AM, Hudson M, et al. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther. 1993;7:317–321.
   PubMed Web of Science ®Google Scholar
• Zimmermann T, Yeates RA, Laufen H, et al. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol. 1994;46:147–150.
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Roos B, Roerhle M, et al. No relevant food effect in man on isavuconazole oral pharmacokinetics: preliminary data. In: ICAAC American Society for Microbiology-Infectious Diseases Society of America (IDSA) 46th annual meeting American Society for Microbiology and Infectious Diseases Society of America. Washington (DC): ICAAC; 2008. Abstract pA-008
   Google Scholar
• Cresemba® [package insert]. Northbrook (IL): Astellas Pharma; 2015.
   Google Scholar
• Purkins L, Wood N, Kleinermans D, et al. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol. 2003;56(Suppl 1):17–23.
   PubMed Web of Science ®Google Scholar
• Patterson R, Coates P. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995a Sep 17–20; San Francisco (CA). Abstract no F78
   Google Scholar
• Seay RE, Larson TA, Toscano JP, et al. Pharmacokinetics of fluconazole in immune-compromised children with leukemia or other hematologic diseases. Pharmacotherapy. 1995;15:52–58.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother. 2010;54:4116–4123.
   PubMed Web of Science ®Google Scholar
• Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother. 2009;53:935–944.
   PubMed Web of Science ®Google Scholar
• Zane NR, Thakker DR. A physiologically based pharmacokinetic model for voriconazole disposition predicts intestinal first-pass metabolism in children. Clin Pharmacokinet. 2014;53:1171–1182.
   PubMed Web of Science ®Google Scholar
• Brown JT, Abdel-Rahman SM. Pediatric pharmacokinetics. In: Benavides N, editor. Pediatric pharmacotherapy. Lenexa (KS): American College of Clinical Pharmacy; 2012. p. 18–33.
   Google Scholar
• Mori M, Kobayashi R, Kato K, et al. Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients. Antimicrob Agents Chemother. 2015;59:1004–1013.
   PubMed Web of Science ®Google Scholar
• Van Der Meer JW, Keuning JJ, Scheijgrond HW, et al. The influence of gastric acidity on the bio-availability of ketoconazole. J Antimicrob Chemother. 1980;6:552–554.
   PubMed Web of Science ®Google Scholar
• Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1988;109:471–473.
   PubMed Web of Science ®Google Scholar
• Piscitelli SC, Goss TF, Wilton JH, et al. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991;35:1765–1771.
   PubMed Web of Science ®Google Scholar
• Carlson JA, Mann HJ, Canafax DM. Effect of pH on disintegration and dissolution of ketoconazole tablets. Am J Hosp Pharm. 1983;40:1334–1336.
   PubMedGoogle Scholar
• Hurwitz A, Ruhl CE, Kimler BF, et al. Gastric function in the elderly: effects on absorption of ketoconazole. J Clin Pharmacol. 2003;43:996–1002.
   PubMed Web of Science ®Google Scholar
• Ginsburg CM, McCracken GH, Olsen K. Pharmacology of ketoconazole suspension in infants and children. Antimicrob Agents Chemother. 1983;23:787–789.
   PubMed Web of Science ®Google Scholar
• Posaconazole FDA Clinical Pharmacology Review. 2013 [cited 2015 Dec 20]. Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM383684.pdf
   Google Scholar
• Sporanox® [package insert]. Titusville (NJ): Janssen Pharmaceuticals; 2014.
   Google Scholar
• Kersemaekers WM, Dogterom P, Xu J, et al. Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation. Antimicrob Agents Chemother. 2015;59:3385–3389.
   PubMed Web of Science ®Google Scholar
• Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother. 1993;37:778–784.
   PubMed Web of Science ®Google Scholar
• Barone JA, Moskovitz BL, Guarnieri J, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother. 1998;42:1862–1865.
   PubMed Web of Science ®Google Scholar
• Van de Velde VJS, Van Peer AP, Heykants JJP, et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Pharmacotherapy. 1996;16:424–428.
   PubMed Web of Science ®Google Scholar
• Krishna G, Ma L, Martinho M, et al. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother. 2012;56:4196–4201.
   PubMed Web of Science ®Google Scholar
• Hens B, Brouwers J, Corsetti M, et al. Supersaturation and precipitation of posaconazole upon entry in the upper small intestine in humans. J Pharm Sci. 2015 Oct 27. doi:10.1002/jps.24690.
   PubMed Web of Science ®Google Scholar
• Kraft WK, Chang PS, van Iersel ML, et al. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother. 2014;58:4020–4025.
   PubMed Web of Science ®Google Scholar
• Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, et al. Reduced oral itraconazole bioavailability by antacid suspension. J Clin Pharm Ther. 2005;30:201–206.
   PubMed Web of Science ®Google Scholar
• Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53:958–966.
   PubMed Web of Science ®Google Scholar
• Ross A, Slain D, Cumpston A, et al. Evaluation of an alternative posaconazole prophylaxis regimen in patients with hematologic malignancies receiving stress ulcer prophylaxis. Int J Antimicrob Agents. 2012;40:557–561.
   PubMed Web of Science ®Google Scholar
• Czinn SJ, Blanchard SS. Developmental anatomy and physiology of the stomach. In: Wyllie R, Hyames JS, editors. Pediatric gastointestinal and liver disease. 4th ed. Philadelphia (PA): Elsevier; 2011.
   Google Scholar
• Gottrand F. Acid-peptic disease. In: Kleinman RE, Sanderson IR, Goulet O, et al., editors. Walker’s pediatric gastointestinal disease: physiology, diagnosis, management. Vol. 1. 5th ed. Hamilton (ON): BC Decker, Inc.; 2008.
   Google Scholar
• Martinez-Jorda R, Rodriguez-Sasiain JM, Suarez JM, et al. Serum binding of ketoconazole in health and disease. Int J Clin Pharm Res. 1990;10:271–276.
   PubMedGoogle Scholar
• Noxafil® [package insert]. Kenilworth (NJ): Schering-Plough; 2008.
   Google Scholar
• Arredondo G, Suárez E, Calvo R, et al. Serum protein binding of itraconazole and fluconazole in patients with diabetes mellitus. J Antimicrob Chemother. 1999;43:305–307.
   PubMed Web of Science ®Google Scholar
• Arredondo G, Calvo R, Marcos F, et al. Protein binding of itraconazole and fluconazole in patients with cancer. Int J Clin Pharmacol Ther. 1995;33:449–452.
   PubMed Web of Science ®Google Scholar
• Arredondo G, Martinez-Jorda R, Calvo R, et al. Protein binding of itraconazole and fluconazole in patients with chronic renal failure. Int J Clin Pharmacol Ther. 1994;32:361–364.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Cornely OA, Buchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother. 2006;50:658–666.
   PubMed Web of Science ®Google Scholar
• Force RW, Nahata MC. Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. Ann Pharmacother. 1995;29:10–15.
   PubMed Web of Science ®Google Scholar
• Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs. 1989;37:310–344.
   PubMed Web of Science ®Google Scholar
• Ruping MJ, Albermann N, Ebinger F, et al. Posaconazole concentrations in the central nervous system. J Antimicrob Chemother. 2008;62:1468–1470.
   PubMed Web of Science ®Google Scholar
• Vanstraelen K, Wauters J, De Loor H, et al. Protein-binding characteristics of voriconazole determined by high-throughput equilibrium dialysis. J Pharm Sci. 2014;103:2565–2570.
   PubMed Web of Science ®Google Scholar
• Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol. 1997;97:663–665.
   PubMed Web of Science ®Google Scholar
• Stern JB, Girard P, Caliandro R. Pleural diffusion of voriconazole in a patient with Aspergillus fumigatus empyema thoracis (letter). Antimicrob Agents Chemother. 2004;48:1065.
   PubMed Web of Science ®Google Scholar
• Weiler S, Fiegl D, MacFarland R, et al. Human tissue distribution of voriconazole. Antimicrob Agents Chemother. 2011;55:925–928.
   PubMed Web of Science ®Google Scholar
• Krzeska I, Yeates RA, Pfaff G. Single dose intravenous pharmacokinetics of fluconazole in infants. Drugs Exp Clin Res. 1993;19:267–271.
   PubMedGoogle Scholar
• van der Elst KC, Pereboom M, van den Heuvel ER, et al. Insufficient fluconazole exposure in pediatric cancer patients and the need for therapeutic drug monitoring in critically ill children. Clin Infect Dis. 2014;59:1527–1533.
   PubMed Web of Science ®Google Scholar
• Lee JW, Seibel NL, Amantea M, et al. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr. 1992;120:987–993.
   PubMed Web of Science ®Google Scholar
• Diflucan® [package insert]. New York (NY): Pfizer; 2011.
   Google Scholar
• O’Day DM, Foulds G, Williams TE, et al. Ocular uptake of fluconazole following oral administration. Arch Ophthalmol. 1990;108:1006–1008.
   PubMed Web of Science ®Google Scholar
• Thaler F, Bernard B, Tod M, et al. Fluconazole penetration in cerebral parenchyma in humans at steady state. Antimicrob Agents Chemother. 1995;39:1154–1156.
   PubMed Web of Science ®Google Scholar
• Mikamo H, Kawazoe K, Sato Y, et al. Penetration of oral fluconazole into gynecological tissues. Antimicrob Agents Chemother. 1999;43:148–151.
   PubMed Web of Science ®Google Scholar
• Nizoral® [package insert]. Titusville (NJ): Janssen Pharmaceuticals; 2013.
   Google Scholar
• Schmitt C, Perel Y, Harousseau JL, et al. Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis. Antimicrob Agents Chemother. 2001;45:1561–1564.
   PubMed Web of Science ®Google Scholar
• De Repentigny L, Ratelle J, Leclerc J-M, et al. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother. 1998;42:404–408.
   PubMed Web of Science ®Google Scholar
• Prentice AG, Warnock DW, Johnson SAN, et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother. 1994;34:247–252.
   PubMed Web of Science ®Google Scholar
• Prentice AG, Warnock DW, Johnson SAN, et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukemia. J Antimicrob Chemother. 1995;36:657–663.
   PubMed Web of Science ®Google Scholar
• Patterson B, Roffey S, Jezequel S, et al. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: disposition in man. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sept 17–20; San Francisco (CA). Abstract no F79.
   Google Scholar
• Yanni SB, Annaert PP, Augustijns P, et al. Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos. 2008;36:1119–1125.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004;48:2166–2172.
   PubMed Web of Science ®Google Scholar
• Driscoll TA, Yu LC, Frangoul H, et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. Antimicrob Agents Chemother. 2011;55:5770–5779.
   PubMed Web of Science ®Google Scholar
• Michael C, Bierbach U, Frenzel K, et al. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob Agents Chemother. 2010;54:3225–3232.
   PubMed Web of Science ®Google Scholar
• Hicks JK, Crews KR, Flynn P, et al. Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics. 2014;15:1065–1078.
   PubMed Web of Science ®Google Scholar
• Malingre MM, Godschalk PC, Klein SK. A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine. Br J Clin Pharmacol. 2012;74:205–206.
   PubMed Web of Science ®Google Scholar
• Dolton MJ, Ray JE, Chen SC, et al. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother. 2012;56:4793–4799.
   PubMed Web of Science ®Google Scholar
• Wood N, Tan K, Purkins L, et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol. 2003;56(Suppl 1):56–61.
   PubMed Web of Science ®Google Scholar
• Ghosal A, Hapangama N, Yuan Y, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos. 2004;32:267–271.
   PubMed Web of Science ®Google Scholar
• Vanstraelen K, Colita A, Bica AM, et al. Pharmacokinetics of Posaconazole oral suspension in children dosed according to body surface area. Pediatr Infect Dis J. 2015 Nov 5;35(2):183–188.
   Web of Science ®Google Scholar
• Ashbee HR, Gilleece MH. Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics. Bone Marrow Transplant. 2012;47:881–894.
   PubMed Web of Science ®Google Scholar
• Ehmer U, Vogel A, Schutte JK, et al. Variation of hepatic glucuronidation: novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology. 2004;39:970–977.
   PubMed Web of Science ®Google Scholar
• Bourcier K, Hyland R, Kempshall S, et al. Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole containing antifungal drugs in human liver microsomes and recombinant UGT enzymes. Drug Metab Dispos. 2010;38:923–929.
   PubMed Web of Science ®Google Scholar
• Karonen T, Laitila J, Niemi M, et al. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations. Eur J Clin Pharmacol. 2012;68:681–688.
   PubMed Web of Science ®Google Scholar
• Raungrut P, Uchaipichat V, Elliot DJ, et al. In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. J Pharmacol Exp Ther. 2010;334:609–618.
   PubMed Web of Science ®Google Scholar
• Putt TL, Duffull SB, Schollum JB, et al. GFR may not accurately predict aspects of proximal tubule drug handling. Eur J Clin Pharmacol. 2014;70:1221–1226.
   PubMed Web of Science ®Google Scholar
• Toon S, Ross CE, Gokal R, et al. An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br J Clin Pharmacol. 1990;29:221–226.
   PubMed Web of Science ®Google Scholar
• Saxen H, Hoppu K, Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin Pharmacol Ther. 1993;54:269–277.
   PubMed Web of Science ®Google Scholar
• Wade KC, Wu D, Kaufman DA, et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother. 2008;52:4043–4049.
   PubMed Web of Science ®Google Scholar
• Miyama T, Takanaga H, Matsuo H, et al. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob Agents Chemother. 1998;42:1738–1744.
   PubMed Web of Science ®Google Scholar
• Sansone-Parsons A, Krishna G, Simon J, et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother. 2007;51:495–502.
   PubMed Web of Science ®Google Scholar
• Cancidas® [package insert]. Whitehouse Station (NJ): Merck & Co., Inc.; 2005.
   Google Scholar
• Mycamine® [package insert]. Northbrook (IL): Astellas Pharma; 2013.
   Google Scholar
• Eraxis® [package insert]. New York (NY): Pfizer; 2012.
   Google Scholar
• Kawada M, Fukuoka N, Kondo M, et al. Pharmacokinetics of prophylactic micafungin in very-low-birth-weight infants. Pediatr Infect Dis J. 2009;28:840–842.
   PubMed Web of Science ®Google Scholar
• Benjamin DK Jr, Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther. 2010;87:93–99.
   PubMed Web of Science ®Google Scholar
• Benjamin DK Jr, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother. 2006;50:632–638.
   PubMed Web of Science ®Google Scholar
• Cohen-Wolkowiez M, Benjamin DK Jr, Piper L, et al. Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Clin Pharmacol Ther. 2011;89:702–707.
   PubMed Web of Science ®Google Scholar
• Okugawa S, Ota Y, Tatsuno K, et al. A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid. Scand J Infect Dis. 2007;39:344–346.
   PubMed Web of Science ®Google Scholar
• Sasaki J, Yamanouchi S, Kudo D, et al. Micafungin concentrations in the plasma and burn eschar of severely burned patients. Antimicrob Agents Chemother. 2012;56:1113–1115.
   PubMed Web of Science ®Google Scholar
• Yamada N, Kumada K, Kishino S, et al. Distribution of micafungin in the tissue fluids of patients with invasive fungal infections. J Infect Chemother. 2011;17:731–734.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Goutelle S, Jelliffe RW, et al. Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients. Antimicrob Agents Chemother. 2010;54:3451–3459.
   PubMed Web of Science ®Google Scholar
• Balani SK, Xu X, Arison BH, et al. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos. 2000;28:1274–1278.
   PubMed Web of Science ®Google Scholar
• Fromtling RA. Micafungin sodium (FK-463). Drugs Today. 2002;38:245–247.
   PubMed Web of Science ®Google Scholar
• Graybill JR. The echinocandins, first novel class of antifungals in two decades: will they live up to their promise? Int J Clin Pract. 2001;55:633–638.
   PubMed Web of Science ®Google Scholar
• Hope WW, Seibel NL, Schwartz CL, et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother. 2007;51:3714–3719.
   PubMed Web of Science ®Google Scholar
• Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother. 2005;49:3317–3324.
   PubMed Web of Science ®Google Scholar
• Hope WW, Smith PB, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother. 2010;54:2633–2637.
   PubMed Web of Science ®Google Scholar
• Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J. 2009;28:412–415.
   PubMed Web of Science ®Google Scholar
• Sandhu P, Lee W, Xu X, et al. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005;33:676–682.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother. 2005;49:4536–4545.
   PubMed Web of Science ®Google Scholar
• Neely M, Jafri HS, Seibel N, et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother. 2009;53:1450–1456.
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother. 2009;53:869–875.
   PubMed Web of Science ®Google Scholar
• Kurz H, Fichtl B. Binding of drugs to tissues. Drug Metab Rev. 1983;14:467–510.
   PubMed Web of Science ®Google Scholar
• MacIntyre AC, Cutler DJ. The potential role of lysosomes in tissue distribution of weak bases. Biopharm Drug Dispos. 1988;9:513–526.
   PubMed Web of Science ®Google Scholar
• Yokogawa K, Ishizaki J, Ohkuma S, et al. Influence of lipophilicity and lysosomal accumulation on tissue distribution kinetics of basic drugs: a physiologically based pharmacokinetic model. Methods Find Exp Clin Pharmacol. 2002;24:81–93.
   PubMedGoogle Scholar
• Haddad S, Restieri C, Krishnan K. Characterization of age-related changes in body weight and organ weights from birth to adolescence in humans. J Toxicol Env Health. 2001;64:453–464.
   PubMed Web of Science ®Google Scholar
• Dugoni BM, Guglielmo BJ, Hollander H. Amphotericin B concentration in cerebrospinal fluid of patients with AIDS and cryptococcal meningitis. Clin Pharm. 1989;8:220–221.
   PubMedGoogle Scholar
• Christiansen KJ, Bernard EM, Gold JW, et al. Distribution and activity of amphotericin B in humans. J Infect Dis. 1985;152:1037–1043.
   PubMed Web of Science ®Google Scholar
• Peterson LR, Kelty RH, Hall WH, et al. Therapy of candida peritonitis: penetration of amphotericin B into peritoneal fluid. Postgrad Med J. 1978;54:340.
   PubMed Web of Science ®Google Scholar
• Noyes FR, McCabe JD, Fekety FR Jr. Acute candida arthritis. J Bone Joint Surg. 1973;55:169.
   PubMed Web of Science ®Google Scholar
• Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr. 1990;116:791–797.
   PubMed Web of Science ®Google Scholar
• Benson JM, Nahata MC. Pharmacokinetics of amphotericin B in children. Antimicrob Agents Chemother. 1989;33:1989–1993.
   PubMed Web of Science ®Google Scholar
• Starke JR, Mason EO Jr, Kramer WG, et al. Pharmacokinetics of amphotericin B in infants and children. J Infect Dis. 1987;155:766–774.
   PubMed Web of Science ®Google Scholar
• Amantea MA, Bowden RA, Forrest A, et al. Population pharmacokinetics and renal-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob Agents Chemother. 1995;39:2042–2047.
   PubMed Web of Science ®Google Scholar
• Janknegt R, De Marie S, Bakker-Wodenberg IA, et al. Liposomal and lipid formulations of amphotericin B: clinical pharmacokinetics. Clin Pharmacokinet. 1992;23:279–291.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Whitcomb P, Piscitelli S, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother. 1997;41:1944–1948.
   PubMed Web of Science ®Google Scholar
• Hong Y, Shaw PJ, Nath CE, et al. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob Agents Chemother. 2006;50:935–942.
   PubMed Web of Science ®Google Scholar
• Nath CE, McLachlan AJ, Shaw PJ, et al. Population pharmacokinetics of amphotericin B in children with malignant diseases. Br J Clin Pharmacol. 2001;52:671–680.
   PubMed Web of Science ®Google Scholar
• Adedoyin A, Bernardo JF, Swenson CE, et al. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob Agents Chemother. 1997;41:2201–2208.
   PubMed Web of Science ®Google Scholar
• Wurthwein G, Groll AH, Hempel G, et al. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother. 2005;49:5092–5098.
   PubMed Web of Science ®Google Scholar
• Polak A. Pharmacokinetics of amphotericin B and flucytosine. Postgrad Med J. 1979;55:667–670.
   PubMed Web of Science ®Google Scholar
• Brouwer AE, Van Kan HJ, Johnson E, et al. Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis. Antimicrob Agents Chemother. 2007;51:1038–1042.
   PubMed Web of Science ®Google Scholar
• Harper KJ, Sawyer WT. Malabsorption of flucytosine in a pediatric patient with Shwachman syndrome. DICP. 1989;23:782–783.
   PubMedGoogle Scholar
• O’Day DM, Head WS, Robinson RD, et al. Intraocular penetration of systemically administered antifungal agents. Curr Eye Res. 1985;4:131–134.
   PubMed Web of Science ®Google Scholar
• Cutler RE, Blair AD, Kelly MR. Flucytosine kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther. 1978;24:333–342.
   PubMed Web of Science ®Google Scholar
• Bennet JE. Flucytosine. Ann Intern Med. 1977;86:319–321.
   PubMed Web of Science ®Google Scholar
• Schonebeck J, Polak A, Fernex M, et al. Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function. Chemotherapy. 1973;18:321–336.
   PubMed Web of Science ®Google Scholar
• Dawborn JK, Page MD, Schiavone DJ, et al. Use of 5-fluorocytosine in patients with impaired renal function. Br Med J. 1973;4:382–384.
   PubMed Web of Science ®Google Scholar
• Block ER. Bennett JE: pharmacological studies with 5-fluorocytosine. Antimicrob Agents Chemother. 1972;1:476–482.
   PubMed Web of Science ®Google Scholar
• Wade DN, Sudlow G. The kinetics of 5-fluorocytosine elimination in man. Aust N Z J Med. 1972;2:153–158.
   PubMedGoogle Scholar
• Soltani M, Tobin CM, Bowker KE, et al. Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory. Int J Antimicrob Agents. 2006;28:574–577.
   PubMed Web of Science ®Google Scholar
• Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53:24–34.
   PubMed Web of Science ®Google Scholar
• Ashbee HR, Barnes RA, Johnson EM, et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014;69:1162–1176.
   PubMed Web of Science ®Google Scholar
• Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014;15:e327–e340.
   PubMed Web of Science ®Google Scholar
• Pasqualotto AC, Howard SJ, Moore CB, et al. Flucytosine therapeutic monitoring: 15 years experience from the UK. J Antimicrob Chemother. 2007;59:791–793.
   PubMed Web of Science ®Google Scholar
• Stamm AM, Diasio RB, Dismukes WE, et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med. 1987;83:236–242.
   PubMed Web of Science ®Google Scholar
• Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45:807–825.
   PubMed Web of Science ®Google Scholar
• Boogaerts MA, Verhoef GE, Zachee P, et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses. 1989;32(Suppl 1):103–108.
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Hahn C, Leutner C, et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses. 1999;42:443–451.
   PubMed Web of Science ®Google Scholar
• Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012;55:1080–1087.
   PubMed Web of Science ®Google Scholar
• Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201–211.
   PubMed Web of Science ®Google Scholar
• Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006;50:1570–1572.
   PubMed Web of Science ®Google Scholar
• Soler-Palacin P, Frick MA, Martin-Nalda A, et al. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. J Antimicrob Chemother. 2012;67:700–706.
   PubMed Web of Science ®Google Scholar
• Hamada Y, Tokimatsu I, Mikamo H, et al. Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. 2013;19:381–392.
   PubMed Web of Science ®Google Scholar
• Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther. 2010;88:115–119.
   PubMed Web of Science ®Google Scholar
• Campoli P, Al Abdallah Q, Robitaille R, et al. Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis. Antimicrob Agents Chemother. 2011;55:5732–5739.
   PubMed Web of Science ®Google Scholar
• Farowski F, Cornely OA, Vehreschild JJ, et al. Intracellular concentrations of posaconazole in different compartments of peripheral blood. Antimicrob Agents Chemother. 2010;54(7):2928–2931.
   PubMed Web of Science ®Google Scholar